Search

Your search keyword '"Guc ZG"' showing total 2 results
Start Over Author "Guc ZG" Search Limiters Full Text
2 results on '"Guc ZG"'

1. cancer recurrence (Deimos Study): A study of the Palliative Care Working

Author

Alkan, A, Yasar, A, Guc, ZG, Gurbuz, M, Basoglu, T, Goksu, SS, Basal, FB, Turk, HM, Ozdemir, O, Cinkir, HY, Guven, DC, Kus, T, Turker, S, Koral, L, Karakas, Y, Ak, N, Paydas, S, Karci, E, Demiray, AG, Demir, A, Alan, O, Keskin, O, Nayir, E, Tanriverdi, O, Yavuzsen, T, Yumuk, PF, Ates, O, Coskun, HS, Turhal, S, and Senler, FC

Subjects
fear of cancer recurrence, oncology, patient-physician relationship, survivor
Abstract

Objective Fear of cancer recurrence (FCR) is an important psychological trauma associated with reduction in the quality of life, disruptions in the level of adjustment, emotional distress and anxiety. The purpose of the study was to evaluate the impact of patient-physician relationship on FCR. Methods The study was designed as a multicentre survey study. The cancer survivors, who were under remission, were evaluated with structured questionnaires. Patient-physician relationship (PPR) scale in which higher scores indicate better relationship and FCR inventory was used. Results Between January and April 2019, 1,580 patients were evaluated. The median age was 57.0 (19-88), and 66% were female. There was high level of FCR scores in 51% of participants. There was a negative correlation between PPR and FCR scores (r = -.134,p < .001). In multivariate analysis, young age, female gender, history of metastasectomy and worse PPR were associated with high levels of FCR. Conclusion It is the first data showing the adverse impact of worse PPR on FCR. The strategies to improve the PPR should be practised. In addition, the cancer survivors, who are under the risk of FCR, should be evaluated and managed. C1 [Alkan, Ali; Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Sch Med, Med Oncol, Mugla, Turkey. [Yasar, Arzu; Gurbuz, Mustafa; Senler, Filiz Cay] Ankara Univ, Med Oncol, Sch Med, Ankara, Turkey. [Guc, Zeynep Gulsum; Yavuzsen, Tugba] Dokuz Eylul Univ, Sch Med, Med Oncol, Izmir, Turkey. [Basoglu, Tugba; Yumuk, Perran Fulden] Marmara Univ, Sch Med, Med Oncol, Istanbul, Turkey. [Goksu, Sema Sezgin; Coskun, Hasan Senol] Akdeniz Univ, Med Oncol, Sch Med, Antalya, Turkey. [Basal, Fatma Bugdayci; Ates, Ozturk] Abdurrahman Yurtarslan Res & Training Hosp, Med Oncol, Ankara, Turkey. [Turk, Haci Mehmet] Bezmialem Univ, Sch Med, Med Oncol, Istanbul, Turkey. [Ozdemir, Ozlem] Izmir Bozyak Res & Training Hosp, Med Oncol, Izmir, Turkey. [Cinkir, Havva Yesil] Gaziantep Univ, Sch Med, Med Oncol, Gaziantep, Turkey. [Guven, Deniz Can] Hacettepe Univ, Med Oncol, Sch Med, Ankara, Turkey. [Kus, Tulay] Dr Ersin Arslan Training & Res Hosp, Med Oncol, Gaziantep, Turkey. [Turker, Sema] Diskapi Yildirim Beyazit Res & Training Hosp, Med Oncol, Ankara, Turkey. [Koral, Lokman] Canakkale Onsekiz Mart Univ, Sch Med, Med Oncol, Canakkale, Turkey. [Karakas, Yusuf] Bodrum Acibadem Hosp, Med Oncol, Mugla, Turkey. [Ak, Naziye] Istanbul Univ, Sch Med, Med Oncol, Istanbul, Turkey. [Paydas, Semra] Cukurova Univ, Med Oncol, Sch Med, Adana, Turkey. [Karci, Ebru] Bagcilar Res & Training Hosp, Med Oncol, Istanbul, Turkey. [Demiray, Atike Gokcen] Pamukkale Univ, Med Oncol, Sch Med, Denizli, Turkey. [Demir, Atakan] Acibadem Maslak Hosp, Med Oncol, Istanbul, Turkey. [Alan, Ozkan] Tekirdag Publ Hosp, Med Oncol, Tekirdag, Turkey. [Keskin, Ozge] Selcuk Univ, Sch Med, Med Oncol, Konya, Turkey. [Nayir, Erdinc] VM Med Pk Mersin Hosp, Med Oncol, Mersin, Turkey. [Turhal, Serdar] Anadolu Med Ctr, Med Oncol, Kocaeli, Turkey.

Published
2020

2. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.

Author

Bilici A, Koca S, Karaagac M, Aydin SG, Eraslan E, Kaplan MA, Ocak B, Goksu SS, Paydas S, Akgul F, Derin S, Ergun Y, Yekeduz E, Erol C, Ozyukseler DT, Demiray AG, Karaca M, Guc ZG, Menekse S, Cinkir HY, Gumusay O, Sakin A, Ozkul O, Demir H, Erdem D, Besiroglu M, Unal OU, Acar R, Koral L, Sahin S, Sakalar T, Bahceci A, Ozveren A, Gunaydin UM, Seker MM, Sunar V, Dal P, Artac M, and Turhal S

Subjects
Adult, Humans, Female, Middle Aged, Male, Retrospective Studies, Turkey epidemiology, Indazoles, Sarcoma pathology, Leiomyosarcoma, Sarcoma, Synovial, Soft Tissue Neoplasms, Neoplasms, Second Primary
Abstract

Aim: Description of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS)., Patients and Methods: This multicenter study is based on retrospective review of hospital medical records of patients (≥ 18 years) treated with pazopanib for non-adipocytic metastatic STS at 37 Oncology clinics across Turkey. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated with further analysis of data on the three most common histological subtypes (leiomyosarcoma [LMS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma [SS]) in the cohort., Results: Data of 552 adults (57.6% women, median age: 52 years) were analyzed. DCR and ORR were 43.1% and 30.8%, respectively. Median PFS was 6.7 months and OS was 13.8 months. For LMS, UPS and SS, median PFSs were 6.1, 5.9 and 7.53 months and median OSs were 15.03, 12.87 and 12.27 months, respectively. ECOG ≥ 2 was associated with poor PFS and OS. Liver metastasis was only a factor for progression. Second-line use of pazopanib (vs. front-line) was associated with better PFS, its use beyond third line predicted worse OS. Adverse events (AE) occurred in 82.7% of patients. Most common AEs were fatigue (58.3%) and anorexia (52.3%) which were graded as ≥ 3 in 8.2% and 7.4% of patients, respectively., Conclusion: Pazopanib is effective and well-tolerated in treatment of non-adipocytic metastatic STS. Its earlier use (at second-line), good performance status may result in better outcomes. Worldwide scientific collaborations are important to gain knowledge on rarer STS subtypes by conducting studies in larger patient populations., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results